New Companies
Monday, 7/6, 07:37 AM
Novartis Buys UK Biotech Myricx Bio for Up to $1.5 Billion to Expand Its Cancer Pipeline
- Novartis has agreed to buy the London biotech Myricx Bio for up to $1.5 billion, $1.1 billion up front and up to $400 million more if the science delivers, to get hold of a new kind of targeted cancer drug.
- It is the latest big-pharma bet on 'antibody-drug conjugates.'